IntraGel Therapeutics, Ltd.

Product and customers

Its TumoCure candidate combines the platform with cisplatin for direct injection into solid tumors, aiming to maintain local drug exposure while limiting systemic effects. The company is advancing this localized delivery approach through clinical development for head-and-neck cancer and broader formulation applications.